(Q34552607)

3 August 2017

1 reference

title

'Biogenerics': the off-patent biotech products (English)

1 reference

3 August 2017

Huub Schellekens

1

1 reference

3 August 2017

Jean-Charles Ryff

series ordinal

2

1 reference

3 August 2017

publication date

1 March 2002

1 reference

Trends in Pharmacological Sciences

3 August 2017

published in

1 reference

3 August 2017

volume

23

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

119-121

1 reference

Upstream strategies to minimize proteolytic degradation upon recombinant production in Escherichia coli

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Getting the glycosylation right: implications for the biotechnology industry

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Effects of ammonia on CHO cell growth, erythropoietin production, and glycosylation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

An enzyme-linked immunosorbent assay (ELISA) for quantitation of adducts of granulocyte-macrophage colony stimulating factor (GM-CSF) and human serum albumin (HSA) in stressed solution mixtures

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Solid-state chemical stability of proteins and peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Instability, stabilization, and formulation of liquid protein pharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Deamidation: a source of microheterogeneity in pharmaceutical proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Degradation products of factor VIII which can lead to increased immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901967-2

7 January 2021

10.1016/S0165-6147(00)01967-2

Identifiers

DOI

1 reference

3 August 2017

1 reference